Last reviewed · How we verify
Surgiphor
Surgiphor is a Small molecule drug developed by Rothman Institute Orthopaedics. It is currently FDA-approved.
Surgiphor is a sterile povidone-iodine solution used for wound irrigation in medical procedures. It has been studied in clinical trials for its effectiveness in reducing the rate of positive deep culture and next-generation sequencing in patients undergoing primary total shoulder arthroplasty.
At a glance
| Generic name | Surgiphor |
|---|---|
| Sponsor | Rothman Institute Orthopaedics |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Surgiphor Us in TSA (PHASE4)
- Surgiphor vs Saline Joints (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Surgiphor CI brief — competitive landscape report
- Surgiphor updates RSS · CI watch RSS
- Rothman Institute Orthopaedics portfolio CI
Frequently asked questions about Surgiphor
What is Surgiphor?
Who makes Surgiphor?
What development phase is Surgiphor in?
Related
- Manufacturer: Rothman Institute Orthopaedics — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing